Clinical implications of discordant viral and immune outcomes following protease inhibitor containing antiretroviral therapy for HIV-infected children

被引:0
|
作者
Carina A. Rodriguez
Sarah Koch
Maureen Goodenow
John W. Sleasman
机构
[1] University of South Florida,Department of Pediatrics, Division of Allergy, Immunology and Rheumatology
[2] College of Medicine,Division of Infectious Diseases
[3] All Children’s Hospital,Department of Pathology, Immunology, and Laboratory Medicine
[4] University of South Florida,undefined
[5] College of Medicine,undefined
[6] All Children’s Hospital,undefined
[7] University of Florida,undefined
[8] College of Medicine,undefined
来源
Immunologic Research | 2008年 / 40卷
关键词
HIV; Protease inhibitor; Thymus; Immune reconstitution; CD4 T cells;
D O I
暂无
中图分类号
学科分类号
摘要
Many HIV-infected children treated with protease inhibitors (PI) reconstitute immunity despite viral breakthrough predicting disease progression. We studied a unique cohort of PI treated children with advanced disease who demonstrated sustained CD4 T cell counts but median post therapy viral load rebounded to >4.0 log10 copies/ml. Phylogenetic relationships between pre- and post-therapy viruses reveals significant bottlenecks for quasispecies with natural polymorphisms mapping outside of protease active site providing selective advantage for emergence. Among discordant subjects post-therapy viruses fell into two phenotypes; high viral loads (median >5.0 log10 copies/ml) and attenuated post-therapy replication (median <4.0 log10 copies/ml). Both groups showed similar degrees of CD4 T cell immune reconstitution and were similar to children who optimally suppressed virus to <400 copies/ml. Both high fit and low fit discordant response groups showed high reconstitution of naïve CD4 CD45RA T cells (median 388 and 357 cells/μl, respectively). Naïve T cells increases suggest virus replicating under PI selective pressure do not impair thymic output. If therapeutic options are limited, selection of therapy which allows immune reconstitution despite suboptimal viral control may be beneficial. This novel paradigm for virus/host interactions may lead to therapeutic approaches to attenuate viral pathogenesis.
引用
收藏
页码:271 / 286
页数:15
相关论文
共 50 条
  • [1] Clinical implications of discordant viral and immune outcomes following protease inhibitor containing antiretroviral therapy for HIV-infected children
    Rodriguez, Carina A.
    Koch, Sarah
    Goodenow, Maureen
    Sleasman, John W.
    IMMUNOLOGIC RESEARCH, 2008, 40 (03) : 271 - 286
  • [2] Protease inhibitor therapy in HIV-infected children
    Feingold, AR
    Rutstein, RM
    Meislich, D
    Brown, T
    Rudy, BJ
    AIDS PATIENT CARE AND STDS, 2000, 14 (11) : 589 - 593
  • [3] Antiretroviral Therapy Outcomes in HIV-Infected Children after Adjusting Protease Inhibitor Dosing during Tuberculosis Treatment
    Frohoff, Cordula
    Moodley, Magendhree
    Fairlie, Lee
    Coovadia, Ashraf
    Moultrie, Harry
    Kuhn, Louise
    Meyers, Tammy
    PLOS ONE, 2011, 6 (02):
  • [4] No Differences of Immune Activation and Microbial Translocation Among HIV-infected Children Receiving Combined Antiretroviral Therapy or Protease Inhibitor Monotherapy
    Falcon-Neyra, Lola
    Benmarzouk-Hidalgo, Omar J.
    Madrid, Lola
    Noguera-Julian, Antoni
    Fortuny, Claudia
    Neth, Olaf
    Lopez-Cortes, Luis
    MEDICINE, 2015, 94 (11) : e521
  • [5] Antiretroviral therapy in HIV-infected children
    Fan, Conghai
    Zhang, Fengchao
    Chen, Chao
    MINERVA PEDIATRICA, 2019, 71 (05) : 455 - 460
  • [6] Viral load in HIV-infected children on high activity antiretroviral therapy
    Resino, Salvador
    Bellon, Jose M.
    Antonio Leon, Juan
    Resino, Rosa
    Munoz-Fernandez, M. Angeles
    MEDICINA CLINICA, 2007, 128 (02): : 49 - 51
  • [7] ANTIRETROVIRAL THERAPY INTERRUPTION AND CLINICAL OUTCOMES IN HIV-INFECTED ADULTS
    Mgbere, Osaro
    Barahmani, Nadia
    Wang, Jason
    Khuwaja, Salma
    Essien, Ekere James
    RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY, 2019, 15 (10): : E39 - E39
  • [8] Mortality and Clinical Outcomes in HIV-Infected Children on Antiretroviral Therapy in Malawi, Lesotho, and Swaziland
    Kabue, Mark M.
    Buck, W. Chris
    Wanless, Sebastian R.
    Cox, Carrie M.
    McCollum, Eric D.
    Caviness, A. Chantal
    Ahmed, Saeed
    Kim, Maria H.
    Thahane, Lineo
    Devlin, Andrew
    Kochelani, Duncan
    Kazembe, Peter N.
    Calles, Nancy R.
    Mizwa, Michael B.
    Schutze, Gordon E.
    Kline, Mark W.
    PEDIATRICS, 2012, 130 (03) : E591 - E599
  • [9] Effect of Lopinavir and Nevirapine Concentrations on Viral Outcomes in Protease Inhibitor-experienced HIV-infected Children
    Moholisa, Retsilisitsoe R.
    Schomaker, Michael
    Kuhn, Louise
    Castel, Sandra
    Wiesner, Lubbe
    Coovadia, Ashraf
    Strehlau, Renate
    Patel, Faeezah
    Pinillos, Francoise
    Abrams, Elaine J.
    Maartens, Gary
    McIlleron, Helen
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2016, 35 (12) : E378 - E383
  • [10] Impact of protease inhibitor-containing combination antiretroviral therapies on height and weight growth in HIV-infected children
    Buchacz, K
    Cervia, JS
    Lindsey, JC
    Hughes, MD
    Seage, GR
    Dankner, WM
    Oleske, JM
    Moye, J
    PEDIATRICS, 2001, 108 (04) : E72